Cholestanol derivative for combined use
AssigneesOtsuka Pharmaceutical Co., Ltd., National University Corporation Gunma University
InventorsShin YAZAWA, Toyo NISHIMURA, Takayuki ASAO
Life of this patent
Estimating the term…
Abstract
The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.
Claims10
A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1):
- (wherein G represents GlcNAc-Gal-, or GlcNAc- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan.
2-10. (canceled)
A method of providing chemotherapy to a cancer patient in need thereof, the method comprising administering to the patient a cholestanol derivative represented by formula (1):
- wherein G represents GlcNAc-Gal or GlcNAc- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan.
Dependencies are inferred from the claim text.